Editorial
Switching haemophilia products and inhibitor risk: a United States' perspective
Danielle Nance,
Danielle Nance
Division of Hematology and Hematologic Malignancies, University of Utah Health Sciences Center, Salt Lake City, UT, USA
Search for more papers by this author George M. Rodgers,
Corresponding Author
George M. Rodgers
Division of Hematology and Hematologic Malignancies, University of Utah Health Sciences Center, Salt Lake City, UT, USA
Correspondence George M. Rodgers, MD, PhD, Division of Hematology and Hematologic Malignancies, University of Utah Health Sciences Center, 30 North 1900 East, Salt Lake City, UT 84132, USA. Tel: 801-213-2076; Fax: 801-581-4136; e-mail:
[email protected]Search for more papers by this author
Danielle Nance,
Danielle Nance
Division of Hematology and Hematologic Malignancies, University of Utah Health Sciences Center, Salt Lake City, UT, USA
Search for more papers by this author George M. Rodgers,
Corresponding Author
George M. Rodgers
Division of Hematology and Hematologic Malignancies, University of Utah Health Sciences Center, Salt Lake City, UT, USA
Correspondence George M. Rodgers, MD, PhD, Division of Hematology and Hematologic Malignancies, University of Utah Health Sciences Center, 30 North 1900 East, Salt Lake City, UT 84132, USA. Tel: 801-213-2076; Fax: 801-581-4136; e-mail:
[email protected]Search for more papers by this author
First published: 21 March 2015
No abstract is available for this article.
References
- 1 Proceedings of the World Federation of Hemophilia's Sixth Global Forum on the Safety and Supply of Treatment Products for Bleeding Disorders. Montreal, Canada, 2009: 8. http://www.wfh.org.
- 2Santagostino E, Auerswald G, Benson G, Dolan G, Jimenez-Yuste V, Lambert T, Ljung R, Morfini M, Remor E, Salek SZ. Switching treatments in haemophilia: is there a risk of inhibitor development? Eur J Haematol, doi:10.1111/ejh.12433.
- 3 Medical and Scientific Advisory Council. Document #216, The National Hemophilia Foundation http://advocacy.hemophilia.org/portfolio/masac-recommendations
- 4Gouw SC, van der Bom JG, Ljung R, et al. Factor VIII products and inhibitor development in severe Hemophilia A. New Engl J Med 2013; 368: 231–9.
- 5Kessler CM, Iorio A. The RODIN (Research of Determinants of INhibitor Development among PUPS with haemophilia) study: the clinical conundrum from the perspective of haemophilia treaters. Haemophilia 2013; 19: 351–4.
- 6Wilmot HV, Hogwood J, Gray E. Recombinant factor IX: discrepancies between one-stage and chromogenic assays. Haemophilia 2014. doi: 10.1111/hae.12449.
- 7Sommer JM, Moore N, McGuffie-Valentine B, Bardan S, Buyue Y, Kamphaus GD, Konkle BA, Pierce GF. Comparative field study evaluating the activity of recombinant factor VIII Fc fusion protein in plasma samples at clinical haemostasis laboratories. Haemophilia 2014; 20: 294–300.
